Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gout | 109 | 2024 | 142 | 40.790 |
Why?
|
Arthroplasty, Replacement, Knee | 55 | 2023 | 133 | 21.750 |
Why?
|
Arthroplasty, Replacement, Hip | 49 | 2024 | 102 | 20.620 |
Why?
|
Arthritis, Rheumatoid | 70 | 2024 | 498 | 18.640 |
Why?
|
Antirheumatic Agents | 58 | 2024 | 231 | 17.200 |
Why?
|
Rheumatology | 58 | 2024 | 136 | 14.380 |
Why?
|
Gout Suppressants | 49 | 2021 | 70 | 13.770 |
Why?
|
Allopurinol | 34 | 2020 | 84 | 12.490 |
Why?
|
Osteoarthritis | 25 | 2023 | 113 | 10.540 |
Why?
|
Osteoarthritis, Knee | 28 | 2023 | 191 | 9.270 |
Why?
|
Medicare | 36 | 2021 | 927 | 8.830 |
Why?
|
Osteoarthritis, Hip | 20 | 2023 | 37 | 8.460 |
Why?
|
Uric Acid | 34 | 2024 | 116 | 7.660 |
Why?
|
Rheumatic Diseases | 33 | 2023 | 96 | 7.540 |
Why?
|
Biological Products | 25 | 2024 | 311 | 6.890 |
Why?
|
Febuxostat | 17 | 2021 | 21 | 6.330 |
Why?
|
Hospitalization | 30 | 2022 | 2217 | 5.760 |
Why?
|
Arthroplasty, Replacement | 13 | 2023 | 40 | 5.470 |
Why?
|
Hyperuricemia | 12 | 2022 | 48 | 5.310 |
Why?
|
Patient Acceptance of Health Care | 16 | 2023 | 619 | 5.190 |
Why?
|
Patient Participation | 17 | 2024 | 478 | 5.140 |
Why?
|
Lupus Erythematosus, Systemic | 10 | 2024 | 251 | 4.900 |
Why?
|
United States | 106 | 2024 | 16336 | 4.280 |
Why?
|
Length of Stay | 28 | 2024 | 2032 | 3.910 |
Why?
|
Lupus Nephritis | 7 | 2019 | 57 | 3.810 |
Why?
|
Comorbidity | 40 | 2021 | 2454 | 3.710 |
Why?
|
Humans | 425 | 2024 | 270683 | 3.600 |
Why?
|
Hospital Mortality | 21 | 2024 | 1407 | 3.440 |
Why?
|
Knee Joint | 11 | 2022 | 170 | 3.270 |
Why?
|
Aged | 157 | 2024 | 72881 | 3.130 |
Why?
|
Immunosuppressive Agents | 10 | 2021 | 1430 | 3.090 |
Why?
|
Shoulder Joint | 8 | 2015 | 91 | 3.040 |
Why?
|
Janus Kinase Inhibitors | 5 | 2023 | 73 | 3.000 |
Why?
|
Quality of Life | 45 | 2023 | 4721 | 2.990 |
Why?
|
Male | 204 | 2024 | 127576 | 2.960 |
Why?
|
Randomized Controlled Trials as Topic | 37 | 2024 | 2734 | 2.880 |
Why?
|
Reoperation | 22 | 2020 | 1449 | 2.870 |
Why?
|
Female | 212 | 2024 | 147229 | 2.820 |
Why?
|
Postoperative Complications | 24 | 2024 | 5834 | 2.810 |
Why?
|
Veterans | 15 | 2022 | 1761 | 2.780 |
Why?
|
Pain Measurement | 30 | 2021 | 995 | 2.660 |
Why?
|
Substance-Related Disorders | 5 | 2021 | 552 | 2.640 |
Why?
|
Risk Factors | 70 | 2021 | 18255 | 2.610 |
Why?
|
Aged, 80 and over | 83 | 2024 | 30801 | 2.600 |
Why?
|
Hospital Charges | 10 | 2024 | 85 | 2.540 |
Why?
|
Middle Aged | 147 | 2024 | 89505 | 2.520 |
Why?
|
Pain, Postoperative | 9 | 2023 | 641 | 2.390 |
Why?
|
Cohort Studies | 44 | 2020 | 9483 | 2.360 |
Why?
|
Clinical Trials as Topic | 31 | 2023 | 3836 | 2.310 |
Why?
|
Vasculitis | 3 | 2021 | 68 | 2.220 |
Why?
|
Treatment Outcome | 96 | 2024 | 34232 | 2.200 |
Why?
|
Pain | 18 | 2023 | 1694 | 2.200 |
Why?
|
Incidence | 37 | 2021 | 5901 | 2.150 |
Why?
|
Methotrexate | 13 | 2022 | 1024 | 2.090 |
Why?
|
Registries | 15 | 2024 | 2285 | 2.060 |
Why?
|
Cocaine | 3 | 2021 | 239 | 2.020 |
Why?
|
Decision Support Techniques | 5 | 2024 | 637 | 1.990 |
Why?
|
Scleroderma, Systemic | 4 | 2020 | 151 | 1.980 |
Why?
|
Arthritis, Psoriatic | 8 | 2022 | 28 | 1.930 |
Why?
|
Sjogren's Syndrome | 3 | 2020 | 108 | 1.920 |
Why?
|
Hip Joint | 5 | 2016 | 59 | 1.900 |
Why?
|
Pyrroles | 7 | 2018 | 594 | 1.860 |
Why?
|
Practice Guidelines as Topic | 20 | 2020 | 2495 | 1.840 |
Why?
|
Communicable Diseases | 4 | 2021 | 210 | 1.830 |
Why?
|
Dementia | 5 | 2018 | 489 | 1.800 |
Why?
|
Self Report | 8 | 2021 | 783 | 1.770 |
Why?
|
Glucocorticoids | 7 | 2021 | 631 | 1.760 |
Why?
|
Arthroplasty, Replacement, Ankle | 3 | 2019 | 3 | 1.730 |
Why?
|
Recovery of Function | 14 | 2017 | 727 | 1.710 |
Why?
|
Activities of Daily Living | 9 | 2019 | 556 | 1.690 |
Why?
|
Periprosthetic Fractures | 4 | 2013 | 6 | 1.680 |
Why?
|
Piperidines | 7 | 2018 | 1067 | 1.670 |
Why?
|
Qualitative Research | 6 | 2024 | 627 | 1.670 |
Why?
|
Surgeons | 5 | 2023 | 546 | 1.650 |
Why?
|
Arthritis, Gouty | 3 | 2019 | 9 | 1.620 |
Why?
|
Humeral Head | 4 | 2011 | 5 | 1.620 |
Why?
|
Telemedicine | 4 | 2022 | 536 | 1.610 |
Why?
|
Low Back Pain | 3 | 2022 | 89 | 1.590 |
Why?
|
Fibromyalgia | 2 | 2022 | 15 | 1.560 |
Why?
|
Cardiovascular Diseases | 9 | 2023 | 2352 | 1.550 |
Why?
|
Hypertension | 10 | 2022 | 1584 | 1.520 |
Why?
|
Arthritis | 5 | 2017 | 146 | 1.490 |
Why?
|
Medicaid | 6 | 2021 | 311 | 1.480 |
Why?
|
Delivery of Health Care | 9 | 2022 | 885 | 1.470 |
Why?
|
Surveys and Questionnaires | 31 | 2022 | 5925 | 1.450 |
Why?
|
Health Status | 14 | 2016 | 616 | 1.450 |
Why?
|
Anti-Anxiety Agents | 2 | 2021 | 94 | 1.440 |
Why?
|
Shoulder Pain | 4 | 2011 | 34 | 1.440 |
Why?
|
Databases, Factual | 16 | 2023 | 2319 | 1.430 |
Why?
|
Physician-Patient Relations | 5 | 2022 | 808 | 1.430 |
Why?
|
Cannabis | 2 | 2021 | 71 | 1.410 |
Why?
|
United States Department of Veterans Affairs | 8 | 2021 | 671 | 1.400 |
Why?
|
Hallucinogens | 2 | 2021 | 55 | 1.400 |
Why?
|
Disease Management | 7 | 2020 | 1106 | 1.390 |
Why?
|
Prosthesis-Related Infections | 4 | 2019 | 246 | 1.370 |
Why?
|
Chondrocalcinosis | 7 | 2021 | 26 | 1.360 |
Why?
|
Emergency Service, Hospital | 5 | 2018 | 1219 | 1.340 |
Why?
|
Hypothyroidism | 2 | 2023 | 208 | 1.340 |
Why?
|
Spondylarthritis | 3 | 2020 | 16 | 1.340 |
Why?
|
Sex Factors | 18 | 2020 | 2217 | 1.330 |
Why?
|
Severity of Illness Index | 24 | 2021 | 4462 | 1.330 |
Why?
|
Diabetes Mellitus | 10 | 2024 | 1124 | 1.310 |
Why?
|
Antibodies, Monoclonal | 15 | 2020 | 4452 | 1.300 |
Why?
|
Chronic Pain | 7 | 2021 | 256 | 1.240 |
Why?
|
Giant Cell Arteritis | 2 | 2020 | 63 | 1.240 |
Why?
|
Arthralgia | 6 | 2021 | 97 | 1.230 |
Why?
|
Age Factors | 21 | 2020 | 5503 | 1.220 |
Why?
|
Proportional Hazards Models | 17 | 2020 | 5115 | 1.220 |
Why?
|
Adrenal Cortex Hormones | 4 | 2016 | 558 | 1.220 |
Why?
|
Patient Education as Topic | 5 | 2020 | 766 | 1.210 |
Why?
|
Patient Satisfaction | 9 | 2019 | 948 | 1.210 |
Why?
|
Osteonecrosis | 3 | 2023 | 56 | 1.210 |
Why?
|
Time Factors | 27 | 2021 | 13261 | 1.210 |
Why?
|
Healthcare Disparities | 6 | 2018 | 646 | 1.210 |
Why?
|
Alcoholism | 2 | 2021 | 322 | 1.190 |
Why?
|
Risk Assessment | 20 | 2023 | 7169 | 1.190 |
Why?
|
Income | 3 | 2023 | 235 | 1.190 |
Why?
|
Plant Extracts | 3 | 2020 | 226 | 1.170 |
Why?
|
Medication Adherence | 6 | 2019 | 521 | 1.160 |
Why?
|
Opioid-Related Disorders | 3 | 2023 | 414 | 1.160 |
Why?
|
Inpatients | 6 | 2021 | 700 | 1.160 |
Why?
|
Urinary Tract Infections | 3 | 2021 | 332 | 1.150 |
Why?
|
Arthritis, Infectious | 2 | 2018 | 72 | 1.150 |
Why?
|
Etanercept | 10 | 2020 | 70 | 1.110 |
Why?
|
Logistic Models | 14 | 2021 | 3520 | 1.110 |
Why?
|
Adult | 65 | 2024 | 80676 | 1.110 |
Why?
|
Cross-Sectional Studies | 16 | 2022 | 4541 | 1.110 |
Why?
|
Spondylitis, Ankylosing | 5 | 2017 | 36 | 1.100 |
Why?
|
Sleep | 3 | 2019 | 430 | 1.100 |
Why?
|
Multivariate Analysis | 13 | 2020 | 4386 | 1.070 |
Why?
|
Disability Evaluation | 7 | 2014 | 240 | 1.060 |
Why?
|
Evidence-Based Medicine | 13 | 2018 | 1133 | 1.050 |
Why?
|
Health Surveys | 8 | 2019 | 415 | 1.050 |
Why?
|
Arthritis, Juvenile | 4 | 2024 | 58 | 1.040 |
Why?
|
Network Meta-Analysis | 5 | 2023 | 53 | 1.040 |
Why?
|
Decision Making | 9 | 2019 | 1344 | 1.040 |
Why?
|
Pyrimidines | 7 | 2018 | 3603 | 1.030 |
Why?
|
Blood Transfusion | 4 | 2024 | 610 | 1.020 |
Why?
|
Prospective Studies | 25 | 2023 | 13302 | 1.020 |
Why?
|
Retrospective Studies | 38 | 2024 | 39492 | 1.020 |
Why?
|
Arthroplasty, Replacement, Elbow | 2 | 2015 | 3 | 1.010 |
Why?
|
Sleep Wake Disorders | 2 | 2019 | 358 | 1.000 |
Why?
|
Sepsis | 2 | 2021 | 667 | 1.000 |
Why?
|
Myocardial Infarction | 6 | 2018 | 1497 | 1.000 |
Why?
|
Consensus | 19 | 2024 | 1084 | 0.990 |
Why?
|
Rheumatologists | 2 | 2021 | 12 | 0.960 |
Why?
|
Health Services | 4 | 2019 | 108 | 0.950 |
Why?
|
Orthopedic Surgeons | 3 | 2020 | 14 | 0.930 |
Why?
|
Surgical Wound Infection | 4 | 2017 | 464 | 0.930 |
Why?
|
Teratogens | 1 | 2024 | 83 | 0.920 |
Why?
|
Clinical Decision-Making | 3 | 2021 | 549 | 0.920 |
Why?
|
Global Health | 12 | 2023 | 696 | 0.910 |
Why?
|
Diabetes Complications | 2 | 2017 | 321 | 0.900 |
Why?
|
Odds Ratio | 11 | 2019 | 2361 | 0.900 |
Why?
|
Cerebrovascular Disorders | 3 | 2015 | 156 | 0.900 |
Why?
|
Drug Therapy, Combination | 10 | 2022 | 2347 | 0.880 |
Why?
|
Abatacept | 8 | 2019 | 39 | 0.870 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 6 | 2020 | 553 | 0.870 |
Why?
|
Arthroplasty, Replacement, Shoulder | 2 | 2020 | 7 | 0.870 |
Why?
|
Pragmatic Clinical Trials as Topic | 1 | 2022 | 26 | 0.840 |
Why?
|
Uveitis | 2 | 2022 | 37 | 0.840 |
Why?
|
Urinary Sphincter, Artificial | 1 | 2022 | 18 | 0.840 |
Why?
|
Opportunistic Infections | 2 | 2015 | 226 | 0.840 |
Why?
|
Penile Implantation | 1 | 2022 | 18 | 0.830 |
Why?
|
Musculoskeletal Diseases | 6 | 2023 | 87 | 0.830 |
Why?
|
Genetic Loci | 2 | 2022 | 500 | 0.830 |
Why?
|
Penile Prosthesis | 1 | 2022 | 30 | 0.830 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 77 | 0.820 |
Why?
|
Ureteral Obstruction | 1 | 2023 | 146 | 0.820 |
Why?
|
Rectal Fistula | 1 | 2022 | 7 | 0.820 |
Why?
|
Primary Health Care | 3 | 2022 | 849 | 0.820 |
Why?
|
Hemiarthroplasty | 2 | 2011 | 4 | 0.820 |
Why?
|
Gracilis Muscle | 1 | 2022 | 9 | 0.810 |
Why?
|
Urinary Fistula | 1 | 2022 | 28 | 0.800 |
Why?
|
Urethral Diseases | 1 | 2022 | 37 | 0.800 |
Why?
|
Urinary Bladder Diseases | 1 | 2022 | 51 | 0.790 |
Why?
|
Tumor Necrosis Factor-alpha | 8 | 2019 | 1589 | 0.790 |
Why?
|
Health Equity | 6 | 2017 | 54 | 0.780 |
Why?
|
Ureter | 1 | 2023 | 215 | 0.780 |
Why?
|
Receptors, Tumor Necrosis Factor | 5 | 2015 | 203 | 0.780 |
Why?
|
Stroke | 5 | 2019 | 1199 | 0.780 |
Why?
|
Antibodies, Monoclonal, Humanized | 11 | 2021 | 3363 | 0.770 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 5 | 2016 | 105 | 0.760 |
Why?
|
Infliximab | 8 | 2018 | 140 | 0.760 |
Why?
|
Botulinum Toxins | 4 | 2012 | 136 | 0.760 |
Why?
|
Hearing Loss | 2 | 2023 | 162 | 0.760 |
Why?
|
Automobile Driving | 1 | 2021 | 32 | 0.760 |
Why?
|
Colchicine | 2 | 2020 | 57 | 0.750 |
Why?
|
Marijuana Smoking | 1 | 2021 | 42 | 0.750 |
Why?
|
Knee Prosthesis | 2 | 2011 | 12 | 0.750 |
Why?
|
Drug Monitoring | 3 | 2020 | 338 | 0.750 |
Why?
|
Obesity | 6 | 2024 | 2995 | 0.740 |
Why?
|
Global Burden of Disease | 5 | 2023 | 28 | 0.740 |
Why?
|
Kidney Diseases | 2 | 2017 | 712 | 0.740 |
Why?
|
Prunus domestica | 1 | 2020 | 1 | 0.740 |
Why?
|
Analgesics | 4 | 2021 | 400 | 0.740 |
Why?
|
Diagnostic Techniques and Procedures | 3 | 2019 | 49 | 0.740 |
Why?
|
Cannabidiol | 1 | 2021 | 42 | 0.740 |
Why?
|
Polymyalgia Rheumatica | 1 | 2020 | 5 | 0.730 |
Why?
|
Body Mass Index | 5 | 2024 | 2299 | 0.730 |
Why?
|
Diet Therapy | 2 | 2020 | 54 | 0.730 |
Why?
|
Health Services Accessibility | 4 | 2019 | 817 | 0.730 |
Why?
|
Marijuana Abuse | 1 | 2021 | 70 | 0.730 |
Why?
|
Acute Kidney Injury | 3 | 2020 | 792 | 0.730 |
Why?
|
Diagnostic Self Evaluation | 1 | 2020 | 32 | 0.710 |
Why?
|
Polymyositis | 1 | 2020 | 13 | 0.710 |
Why?
|
Erectile Dysfunction | 1 | 2022 | 216 | 0.710 |
Why?
|
Adalimumab | 7 | 2022 | 45 | 0.710 |
Why?
|
Follow-Up Studies | 16 | 2022 | 15198 | 0.700 |
Why?
|
Atrial Fibrillation | 2 | 2019 | 799 | 0.700 |
Why?
|
Geriatric Assessment | 2 | 2018 | 292 | 0.700 |
Why?
|
Minnesota | 7 | 2016 | 103 | 0.690 |
Why?
|
Finches | 1 | 2019 | 6 | 0.690 |
Why?
|
Dyslipidemias | 1 | 2022 | 242 | 0.690 |
Why?
|
Social Perception | 1 | 2020 | 74 | 0.690 |
Why?
|
Tai Ji | 1 | 2019 | 15 | 0.690 |
Why?
|
Range of Motion, Articular | 4 | 2017 | 145 | 0.690 |
Why?
|
Knee Injuries | 1 | 2019 | 66 | 0.670 |
Why?
|
Immunoconjugates | 4 | 2010 | 302 | 0.670 |
Why?
|
Elective Surgical Procedures | 5 | 2017 | 263 | 0.670 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2024 | 1280 | 0.670 |
Why?
|
Prostatectomy | 1 | 2024 | 1004 | 0.670 |
Why?
|
Hospitals, County | 1 | 2019 | 29 | 0.670 |
Why?
|
Cost of Illness | 4 | 2017 | 513 | 0.660 |
Why?
|
Wounds and Injuries | 6 | 2020 | 427 | 0.660 |
Why?
|
Immunologic Factors | 3 | 2012 | 667 | 0.650 |
Why?
|
Myositis | 2 | 2022 | 89 | 0.650 |
Why?
|
Patient Discharge | 6 | 2020 | 714 | 0.650 |
Why?
|
Culturally Competent Care | 1 | 2019 | 50 | 0.650 |
Why?
|
Physicians | 3 | 2022 | 914 | 0.650 |
Why?
|
Patient Reported Outcome Measures | 4 | 2023 | 836 | 0.650 |
Why?
|
Phytotherapy | 2 | 2020 | 116 | 0.650 |
Why?
|
Endometriosis | 1 | 2022 | 240 | 0.640 |
Why?
|
Drug Hypersensitivity | 1 | 2020 | 129 | 0.640 |
Why?
|
Cocaine-Related Disorders | 1 | 2021 | 237 | 0.640 |
Why?
|
Prosthesis Failure | 4 | 2013 | 229 | 0.640 |
Why?
|
Hospitals, Veterans | 3 | 2019 | 413 | 0.630 |
Why?
|
Vulnerable Populations | 5 | 2017 | 194 | 0.630 |
Why?
|
Outpatient Clinics, Hospital | 3 | 2019 | 97 | 0.630 |
Why?
|
Botulinum Toxins, Type A | 3 | 2010 | 193 | 0.630 |
Why?
|
Symptom Flare Up | 6 | 2021 | 29 | 0.630 |
Why?
|
Population Surveillance | 2 | 2019 | 646 | 0.630 |
Why?
|
Physical Therapy Modalities | 1 | 2018 | 97 | 0.620 |
Why?
|
Drug Prescriptions | 2 | 2018 | 310 | 0.620 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 5 | 2016 | 1049 | 0.620 |
Why?
|
Ultrasonography | 3 | 2021 | 1926 | 0.620 |
Why?
|
Patient Readmission | 4 | 2017 | 598 | 0.620 |
Why?
|
Coronary Disease | 4 | 2021 | 811 | 0.610 |
Why?
|
Quality-Adjusted Life Years | 10 | 2023 | 242 | 0.600 |
Why?
|
Robotic Surgical Procedures | 1 | 2024 | 520 | 0.580 |
Why?
|
Health Status Indicators | 3 | 2019 | 223 | 0.580 |
Why?
|
Sacroiliac Joint | 1 | 2017 | 20 | 0.580 |
Why?
|
Spiro Compounds | 1 | 2017 | 59 | 0.580 |
Why?
|
Forecasting | 5 | 2013 | 707 | 0.580 |
Why?
|
Research Design | 16 | 2021 | 1598 | 0.570 |
Why?
|
Pneumonia | 3 | 2021 | 761 | 0.570 |
Why?
|
Thiazoles | 2 | 2012 | 730 | 0.570 |
Why?
|
Furans | 1 | 2017 | 106 | 0.570 |
Why?
|
Back Pain | 1 | 2017 | 61 | 0.570 |
Why?
|
Substance P | 1 | 2017 | 72 | 0.560 |
Why?
|
Attitude to Health | 2 | 2020 | 467 | 0.560 |
Why?
|
Macular Degeneration | 1 | 2018 | 124 | 0.560 |
Why?
|
Sickness Impact Profile | 3 | 2011 | 139 | 0.560 |
Why?
|
Patient Preference | 3 | 2020 | 229 | 0.560 |
Why?
|
Urate Oxidase | 3 | 2012 | 35 | 0.550 |
Why?
|
Patient Outcome Assessment | 2 | 2015 | 247 | 0.550 |
Why?
|
Uricosuric Agents | 2 | 2020 | 5 | 0.550 |
Why?
|
Physical Fitness | 3 | 2016 | 125 | 0.550 |
Why?
|
Health Resources | 1 | 2018 | 171 | 0.550 |
Why?
|
Fees and Charges | 1 | 2016 | 17 | 0.540 |
Why?
|
Review Literature as Topic | 5 | 2017 | 77 | 0.540 |
Why?
|
Research | 3 | 2014 | 436 | 0.540 |
Why?
|
Decision Support Systems, Clinical | 1 | 2019 | 257 | 0.530 |
Why?
|
Chronic Disease | 13 | 2015 | 1856 | 0.530 |
Why?
|
Consumer Behavior | 1 | 2016 | 49 | 0.530 |
Why?
|
Self Care | 1 | 2017 | 231 | 0.530 |
Why?
|
Joint Prosthesis | 3 | 2011 | 14 | 0.530 |
Why?
|
Prunus | 1 | 2015 | 1 | 0.520 |
Why?
|
Fruit and Vegetable Juices | 1 | 2015 | 5 | 0.520 |
Why?
|
Drug Substitution | 1 | 2015 | 87 | 0.520 |
Why?
|
Prosthesis Design | 3 | 2022 | 794 | 0.520 |
Why?
|
Reproducibility of Results | 14 | 2021 | 6193 | 0.510 |
Why?
|
Chemokines | 1 | 2017 | 318 | 0.510 |
Why?
|
Inflammation | 5 | 2022 | 2570 | 0.510 |
Why?
|
Tobacco Use | 1 | 2015 | 63 | 0.510 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2020 | 817 | 0.510 |
Why?
|
Quadriceps Muscle | 1 | 2015 | 12 | 0.510 |
Why?
|
Biological Factors | 1 | 2015 | 48 | 0.500 |
Why?
|
Chondroitin Sulfates | 1 | 2015 | 22 | 0.500 |
Why?
|
Congresses as Topic | 1 | 2017 | 308 | 0.500 |
Why?
|
Hospitals, Low-Volume | 1 | 2015 | 56 | 0.500 |
Why?
|
Ankle Joint | 1 | 2015 | 38 | 0.500 |
Why?
|
Drug Therapy | 1 | 2015 | 204 | 0.490 |
Why?
|
Tacrolimus | 1 | 2016 | 347 | 0.490 |
Why?
|
Gene-Environment Interaction | 1 | 2015 | 167 | 0.480 |
Why?
|
Complementary Therapies | 1 | 2016 | 132 | 0.480 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2018 | 241 | 0.480 |
Why?
|
Hospitals, High-Volume | 1 | 2015 | 79 | 0.480 |
Why?
|
Depression | 6 | 2018 | 1766 | 0.480 |
Why?
|
Depressive Disorder | 1 | 2018 | 574 | 0.480 |
Why?
|
Attitude of Health Personnel | 4 | 2021 | 956 | 0.470 |
Why?
|
Synovitis | 2 | 2004 | 23 | 0.470 |
Why?
|
Dietary Supplements | 2 | 2016 | 585 | 0.470 |
Why?
|
Drugs, Investigational | 1 | 2015 | 135 | 0.470 |
Why?
|
Peripheral Arterial Disease | 1 | 2018 | 286 | 0.470 |
Why?
|
Cooperative Behavior | 2 | 2015 | 312 | 0.460 |
Why?
|
Comparative Effectiveness Research | 4 | 2017 | 135 | 0.460 |
Why?
|
Peripheral Vascular Diseases | 1 | 2015 | 139 | 0.460 |
Why?
|
Arthroplasty | 3 | 2011 | 23 | 0.460 |
Why?
|
Brassica napus | 3 | 2012 | 5 | 0.460 |
Why?
|
Smoking | 3 | 2011 | 2524 | 0.450 |
Why?
|
Practice Patterns, Physicians' | 2 | 2021 | 1347 | 0.450 |
Why?
|
Hospital Costs | 3 | 2021 | 244 | 0.440 |
Why?
|
Plant Proteins | 3 | 2013 | 132 | 0.440 |
Why?
|
Prognosis | 14 | 2021 | 22243 | 0.440 |
Why?
|
Mortality | 3 | 2021 | 374 | 0.440 |
Why?
|
Predictive Value of Tests | 9 | 2016 | 5031 | 0.440 |
Why?
|
Adjuvants, Immunologic | 1 | 2017 | 697 | 0.440 |
Why?
|
Calcinosis | 3 | 2021 | 438 | 0.440 |
Why?
|
HLA-B Antigens | 1 | 2013 | 59 | 0.440 |
Why?
|
Placebos | 4 | 2021 | 448 | 0.440 |
Why?
|
Polyethylene Glycols | 4 | 2012 | 636 | 0.430 |
Why?
|
Arrhythmias, Cardiac | 1 | 2017 | 509 | 0.430 |
Why?
|
Administrative Claims, Healthcare | 3 | 2017 | 14 | 0.430 |
Why?
|
Rural Population | 1 | 2015 | 301 | 0.420 |
Why?
|
Symptom Assessment | 3 | 2020 | 276 | 0.420 |
Why?
|
Rituximab | 5 | 2017 | 1557 | 0.410 |
Why?
|
Validation Studies as Topic | 1 | 2012 | 44 | 0.410 |
Why?
|
Arabidopsis Proteins | 2 | 2013 | 50 | 0.400 |
Why?
|
Precision Medicine | 2 | 2017 | 1200 | 0.400 |
Why?
|
Tomography, X-Ray Computed | 4 | 2022 | 7735 | 0.400 |
Why?
|
Parkinson Disease | 1 | 2019 | 714 | 0.400 |
Why?
|
Exercise | 3 | 2021 | 1220 | 0.400 |
Why?
|
Weight Loss | 3 | 2024 | 646 | 0.390 |
Why?
|
Health Personnel | 3 | 2021 | 649 | 0.390 |
Why?
|
Prevalence | 10 | 2023 | 3399 | 0.390 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 378 | 0.390 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2024 | 5029 | 0.390 |
Why?
|
Thromboembolism | 2 | 2011 | 159 | 0.390 |
Why?
|
Arabidopsis | 2 | 2013 | 78 | 0.390 |
Why?
|
Protein Kinase Inhibitors | 3 | 2017 | 4893 | 0.390 |
Why?
|
Health Care Costs | 2 | 2016 | 719 | 0.380 |
Why?
|
Radiography | 6 | 2017 | 1944 | 0.380 |
Why?
|
Propensity Score | 3 | 2020 | 784 | 0.380 |
Why?
|
Biomarkers | 11 | 2022 | 5173 | 0.370 |
Why?
|
Peptic Ulcer | 1 | 2011 | 144 | 0.370 |
Why?
|
Terminology as Topic | 2 | 2017 | 427 | 0.370 |
Why?
|
Drug Eruptions | 1 | 2013 | 267 | 0.370 |
Why?
|
Photosynthesis | 2 | 2012 | 16 | 0.370 |
Why?
|
Exercise Therapy | 3 | 2023 | 293 | 0.370 |
Why?
|
Patients | 3 | 2022 | 258 | 0.360 |
Why?
|
Tuberculosis | 2 | 2017 | 589 | 0.360 |
Why?
|
Young Adult | 12 | 2024 | 22129 | 0.350 |
Why?
|
Age Distribution | 4 | 2021 | 715 | 0.350 |
Why?
|
Delphi Technique | 5 | 2019 | 253 | 0.350 |
Why?
|
Self Disclosure | 1 | 2009 | 31 | 0.350 |
Why?
|
Health Status Disparities | 1 | 2013 | 314 | 0.340 |
Why?
|
Prostheses and Implants | 1 | 2012 | 302 | 0.340 |
Why?
|
Light-Harvesting Protein Complexes | 1 | 2009 | 4 | 0.340 |
Why?
|
Xanthine Oxidase | 2 | 2022 | 20 | 0.340 |
Why?
|
Viral Core Proteins | 1 | 2009 | 24 | 0.340 |
Why?
|
Creatinine | 3 | 2023 | 552 | 0.340 |
Why?
|
Efficiency | 1 | 2010 | 96 | 0.340 |
Why?
|
Triazoles | 3 | 2019 | 630 | 0.330 |
Why?
|
Hypnotics and Sedatives | 2 | 2021 | 222 | 0.330 |
Why?
|
Databases as Topic | 1 | 2009 | 140 | 0.330 |
Why?
|
Calcium Pyrophosphate | 4 | 2021 | 8 | 0.330 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2010 | 132 | 0.330 |
Why?
|
Sex Distribution | 3 | 2020 | 510 | 0.330 |
Why?
|
Perioperative Care | 3 | 2017 | 461 | 0.330 |
Why?
|
Morbidity | 4 | 2020 | 414 | 0.320 |
Why?
|
Cyclophosphamide | 1 | 2016 | 3144 | 0.320 |
Why?
|
Sample Size | 1 | 2009 | 212 | 0.320 |
Why?
|
Remission Induction | 6 | 2021 | 3621 | 0.320 |
Why?
|
Internet | 4 | 2019 | 730 | 0.320 |
Why?
|
Premenopause | 1 | 2009 | 136 | 0.320 |
Why?
|
Organizational Innovation | 2 | 2021 | 73 | 0.320 |
Why?
|
Drug Delivery Systems | 3 | 2011 | 682 | 0.310 |
Why?
|
Kidney Failure, Chronic | 1 | 2016 | 983 | 0.310 |
Why?
|
Treatment Failure | 3 | 2017 | 1433 | 0.310 |
Why?
|
Heart Diseases | 2 | 2011 | 756 | 0.300 |
Why?
|
Hospitals | 1 | 2011 | 494 | 0.300 |
Why?
|
Thioglycolates | 2 | 2017 | 9 | 0.300 |
Why?
|
Staphylococcus aureus | 1 | 2011 | 559 | 0.300 |
Why?
|
Endpoint Determination | 2 | 2018 | 180 | 0.300 |
Why?
|
Child Mortality | 2 | 2019 | 24 | 0.290 |
Why?
|
Cluster Analysis | 2 | 2022 | 1082 | 0.290 |
Why?
|
Patient Acuity | 2 | 2017 | 76 | 0.290 |
Why?
|
Fusarium | 1 | 2007 | 52 | 0.290 |
Why?
|
Gene Expression Regulation, Plant | 1 | 2007 | 73 | 0.290 |
Why?
|
Immunoglobulin G | 5 | 2015 | 1060 | 0.280 |
Why?
|
Certolizumab Pegol | 2 | 2016 | 8 | 0.280 |
Why?
|
Anxiety Disorders | 1 | 2013 | 715 | 0.280 |
Why?
|
Health Literacy | 3 | 2019 | 121 | 0.280 |
Why?
|
Quality Indicators, Health Care | 1 | 2010 | 374 | 0.280 |
Why?
|
Evidence-Based Practice | 5 | 2017 | 131 | 0.270 |
Why?
|
Diphtheria Toxoid | 1 | 2006 | 13 | 0.270 |
Why?
|
Data Collection | 2 | 2022 | 640 | 0.270 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2022 | 365 | 0.270 |
Why?
|
Interleukin-17 | 2 | 2018 | 264 | 0.270 |
Why?
|
Neoplasms | 5 | 2023 | 15703 | 0.270 |
Why?
|
Staphylococcal Infections | 1 | 2011 | 675 | 0.270 |
Why?
|
Polyesters | 1 | 2006 | 63 | 0.270 |
Why?
|
Infant Mortality | 2 | 2019 | 192 | 0.270 |
Why?
|
Sensitivity and Specificity | 6 | 2021 | 5122 | 0.260 |
Why?
|
Bone Density | 1 | 2009 | 470 | 0.260 |
Why?
|
Prostatic Neoplasms | 2 | 2022 | 5938 | 0.260 |
Why?
|
Freezing | 1 | 2005 | 61 | 0.260 |
Why?
|
Immunity, Mucosal | 1 | 2006 | 113 | 0.260 |
Why?
|
Pandemics | 4 | 2022 | 1627 | 0.260 |
Why?
|
Quality of Health Care | 1 | 2010 | 643 | 0.260 |
Why?
|
Bone and Bones | 1 | 2009 | 604 | 0.260 |
Why?
|
Utilization Review | 2 | 2016 | 52 | 0.260 |
Why?
|
Chi-Square Distribution | 3 | 2015 | 1354 | 0.250 |
Why?
|
Standard of Care | 2 | 2017 | 270 | 0.250 |
Why?
|
Administration, Oral | 3 | 2023 | 1583 | 0.250 |
Why?
|
Insurance Claim Review | 2 | 2018 | 76 | 0.250 |
Why?
|
Life Expectancy | 4 | 2020 | 138 | 0.250 |
Why?
|
Nanostructures | 1 | 2006 | 100 | 0.250 |
Why?
|
Meta-Analysis as Topic | 3 | 2017 | 282 | 0.250 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2018 | 333 | 0.250 |
Why?
|
Stem Cell Transplantation | 1 | 2012 | 1384 | 0.250 |
Why?
|
Feasibility Studies | 5 | 2020 | 2364 | 0.250 |
Why?
|
Double-Blind Method | 3 | 2017 | 2662 | 0.250 |
Why?
|
Societies, Medical | 5 | 2021 | 1399 | 0.250 |
Why?
|
Transcription Factors | 3 | 2013 | 5361 | 0.240 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 1904 | 0.240 |
Why?
|
Early Diagnosis | 2 | 2017 | 303 | 0.240 |
Why?
|
Regression Analysis | 2 | 2018 | 1569 | 0.240 |
Why?
|
Bayes Theorem | 3 | 2021 | 1057 | 0.240 |
Why?
|
Biosimilar Pharmaceuticals | 1 | 2024 | 16 | 0.240 |
Why?
|
Proof of Concept Study | 1 | 2024 | 56 | 0.230 |
Why?
|
Reference Values | 3 | 2015 | 1129 | 0.230 |
Why?
|
Metacarpus | 1 | 2003 | 6 | 0.230 |
Why?
|
Scaphoid Bone | 1 | 2003 | 3 | 0.230 |
Why?
|
Osteolysis, Essential | 1 | 2003 | 8 | 0.230 |
Why?
|
Hearing Aids | 1 | 2023 | 16 | 0.230 |
Why?
|
Talus | 1 | 2003 | 12 | 0.230 |
Why?
|
Contraception | 1 | 2024 | 68 | 0.230 |
Why?
|
Patella | 1 | 2003 | 41 | 0.220 |
Why?
|
Eczema | 1 | 2023 | 37 | 0.220 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 4644 | 0.220 |
Why?
|
Public Opinion | 2 | 2021 | 89 | 0.220 |
Why?
|
Adaptation, Physiological | 1 | 2005 | 365 | 0.220 |
Why?
|
Tinnitus | 1 | 2023 | 39 | 0.220 |
Why?
|
Dermatitis, Atopic | 1 | 2023 | 52 | 0.220 |
Why?
|
Ileum | 1 | 2023 | 168 | 0.220 |
Why?
|
Acclimatization | 2 | 2013 | 43 | 0.220 |
Why?
|
Adolescent | 9 | 2024 | 32324 | 0.210 |
Why?
|
Escherichia coli | 1 | 2009 | 1221 | 0.210 |
Why?
|
Consensus Development Conferences as Topic | 4 | 2015 | 80 | 0.210 |
Why?
|
Constriction, Pathologic | 1 | 2023 | 324 | 0.210 |
Why?
|
Quality Assurance, Health Care | 2 | 2019 | 603 | 0.200 |
Why?
|
Pain Management | 2 | 2019 | 703 | 0.200 |
Why?
|
Controlled Clinical Trials as Topic | 2 | 2014 | 35 | 0.200 |
Why?
|
United Kingdom | 1 | 2022 | 281 | 0.200 |
Why?
|
Vaccination | 2 | 2021 | 1176 | 0.200 |
Why?
|
Postoperative Period | 2 | 2016 | 673 | 0.200 |
Why?
|
Amphetamines | 1 | 2021 | 11 | 0.200 |
Why?
|
Overweight | 2 | 2017 | 494 | 0.200 |
Why?
|
Anastomosis, Surgical | 1 | 2023 | 376 | 0.200 |
Why?
|
Socioeconomic Factors | 6 | 2019 | 1263 | 0.200 |
Why?
|
Antigens | 2 | 2017 | 297 | 0.200 |
Why?
|
Organizations | 1 | 2021 | 23 | 0.200 |
Why?
|
Injections, Intra-Articular | 3 | 2010 | 35 | 0.200 |
Why?
|
Adverse Outcome Pathways | 1 | 2021 | 2 | 0.200 |
Why?
|
Drug Design | 2 | 2015 | 383 | 0.200 |
Why?
|
Volatilization | 1 | 2021 | 8 | 0.200 |
Why?
|
Disease Susceptibility | 2 | 2015 | 546 | 0.200 |
Why?
|
Amphetamine | 1 | 2021 | 21 | 0.190 |
Why?
|
Occupational Stress | 1 | 2021 | 14 | 0.190 |
Why?
|
Erythrocytes | 2 | 2017 | 345 | 0.190 |
Why?
|
Communication | 2 | 2019 | 908 | 0.190 |
Why?
|
Disease Progression | 5 | 2017 | 6888 | 0.190 |
Why?
|
Urinary Bladder | 1 | 2024 | 583 | 0.190 |
Why?
|
Algorithms | 2 | 2012 | 3986 | 0.190 |
Why?
|
Dronabinol | 1 | 2021 | 41 | 0.190 |
Why?
|
Attitude to Computers | 1 | 2021 | 75 | 0.190 |
Why?
|
Observational Studies as Topic | 3 | 2020 | 155 | 0.190 |
Why?
|
Patient-Centered Care | 1 | 2024 | 317 | 0.190 |
Why?
|
Disabled Persons | 2 | 2020 | 123 | 0.190 |
Why?
|
Physical Therapists | 1 | 2020 | 6 | 0.180 |
Why?
|
Rotator Cuff Tear Arthropathy | 1 | 2020 | 2 | 0.180 |
Why?
|
Pilot Projects | 4 | 2017 | 2868 | 0.180 |
Why?
|
Synovial Fluid | 1 | 2020 | 26 | 0.180 |
Why?
|
Capsules | 1 | 2020 | 55 | 0.180 |
Why?
|
Organizational Culture | 1 | 2021 | 116 | 0.180 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2022 | 363 | 0.180 |
Why?
|
Job Satisfaction | 1 | 2021 | 131 | 0.180 |
Why?
|
Spleen | 2 | 2017 | 692 | 0.180 |
Why?
|
Rotator Cuff | 1 | 2020 | 35 | 0.180 |
Why?
|
Psychometrics | 4 | 2014 | 962 | 0.180 |
Why?
|
Bias | 1 | 2021 | 220 | 0.180 |
Why?
|
Exercise Movement Techniques | 1 | 2019 | 3 | 0.180 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 559 | 0.180 |
Why?
|
Workload | 1 | 2021 | 203 | 0.180 |
Why?
|
Long Term Adverse Effects | 1 | 2019 | 23 | 0.170 |
Why?
|
Health Care Surveys | 1 | 2021 | 444 | 0.170 |
Why?
|
Fatigue | 3 | 2024 | 1267 | 0.170 |
Why?
|
Midwestern United States | 2 | 2009 | 20 | 0.170 |
Why?
|
Colitis, Ulcerative | 1 | 2022 | 275 | 0.170 |
Why?
|
Survival Rate | 4 | 2017 | 12448 | 0.170 |
Why?
|
Goals | 2 | 2018 | 193 | 0.170 |
Why?
|
Smoking Cessation | 2 | 2018 | 765 | 0.170 |
Why?
|
Los Angeles | 1 | 2019 | 33 | 0.170 |
Why?
|
Linear Models | 2 | 2015 | 1105 | 0.170 |
Why?
|
Pamphlets | 1 | 2019 | 33 | 0.170 |
Why?
|
Ustekinumab | 1 | 2018 | 2 | 0.170 |
Why?
|
Enthesopathy | 1 | 2018 | 3 | 0.170 |
Why?
|
Spondylitis | 1 | 2018 | 8 | 0.170 |
Why?
|
Quantitative Trait Loci | 1 | 2021 | 384 | 0.170 |
Why?
|
Anxiety | 2 | 2018 | 1245 | 0.160 |
Why?
|
Interleukin-23 | 1 | 2018 | 32 | 0.160 |
Why?
|
Patient Advocacy | 1 | 2019 | 91 | 0.160 |
Why?
|
Technology Assessment, Biomedical | 1 | 2019 | 63 | 0.160 |
Why?
|
Crohn Disease | 1 | 2022 | 367 | 0.160 |
Why?
|
International Cooperation | 2 | 2018 | 322 | 0.160 |
Why?
|
Mice, Inbred BALB C | 3 | 2017 | 2403 | 0.160 |
Why?
|
Janus Kinase 1 | 1 | 2019 | 125 | 0.160 |
Why?
|
Nurses | 1 | 2019 | 84 | 0.160 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 233 | 0.160 |
Why?
|
Autoimmune Diseases | 1 | 2022 | 418 | 0.160 |
Why?
|
Longitudinal Studies | 4 | 2017 | 2052 | 0.160 |
Why?
|
Hospitals, Community | 1 | 2019 | 81 | 0.160 |
Why?
|
Models, Statistical | 3 | 2015 | 1205 | 0.160 |
Why?
|
Occupational Therapy | 1 | 2018 | 47 | 0.160 |
Why?
|
Professional-Patient Relations | 1 | 2019 | 117 | 0.160 |
Why?
|
Azetidines | 1 | 2018 | 91 | 0.160 |
Why?
|
Analysis of Variance | 2 | 2013 | 2327 | 0.160 |
Why?
|
Delayed Diagnosis | 1 | 2019 | 150 | 0.150 |
Why?
|
Social Class | 1 | 2019 | 325 | 0.150 |
Why?
|
Workflow | 1 | 2019 | 288 | 0.150 |
Why?
|
Learning | 1 | 2021 | 421 | 0.150 |
Why?
|
Social Participation | 2 | 2016 | 23 | 0.150 |
Why?
|
Public Health | 2 | 2019 | 308 | 0.150 |
Why?
|
Diclofenac | 1 | 2017 | 12 | 0.150 |
Why?
|
Interleukin-12 | 1 | 2018 | 265 | 0.150 |
Why?
|
Health Plan Implementation | 1 | 2017 | 91 | 0.150 |
Why?
|
Hypersensitivity, Delayed | 1 | 2017 | 104 | 0.150 |
Why?
|
Therapies, Investigational | 1 | 2017 | 63 | 0.150 |
Why?
|
Macrophages, Peritoneal | 1 | 2017 | 69 | 0.140 |
Why?
|
Antibiotics, Antitubercular | 1 | 2017 | 42 | 0.140 |
Why?
|
Free Radical Scavengers | 1 | 2017 | 83 | 0.140 |
Why?
|
Purines | 1 | 2018 | 275 | 0.140 |
Why?
|
Neck Pain | 1 | 2017 | 40 | 0.140 |
Why?
|
Manitoba | 1 | 2016 | 5 | 0.140 |
Why?
|
Blood Pressure | 2 | 2021 | 1527 | 0.140 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2009 | 869 | 0.140 |
Why?
|
Cytokines | 2 | 2017 | 2867 | 0.140 |
Why?
|
Choice Behavior | 1 | 2019 | 254 | 0.140 |
Why?
|
Sheep | 1 | 2017 | 265 | 0.140 |
Why?
|
Case-Control Studies | 2 | 2018 | 6243 | 0.140 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 3518 | 0.140 |
Why?
|
Methylprednisolone | 1 | 2017 | 189 | 0.140 |
Why?
|
Leadership | 1 | 2019 | 273 | 0.140 |
Why?
|
Risk | 2 | 2018 | 1998 | 0.140 |
Why?
|
Cold Temperature | 2 | 2013 | 131 | 0.130 |
Why?
|
Cyclosporine | 1 | 2017 | 284 | 0.130 |
Why?
|
Checklist | 1 | 2017 | 132 | 0.130 |
Why?
|
Protective Factors | 1 | 2016 | 110 | 0.130 |
Why?
|
Skin Transplantation | 1 | 2017 | 180 | 0.130 |
Why?
|
Insurance, Health | 1 | 2018 | 259 | 0.130 |
Why?
|
Rifampin | 1 | 2017 | 205 | 0.130 |
Why?
|
Health Transition | 1 | 2015 | 10 | 0.130 |
Why?
|
Massachusetts | 1 | 2015 | 125 | 0.130 |
Why?
|
Organic Anion Transporters | 1 | 2015 | 22 | 0.130 |
Why?
|
Patient Care Team | 1 | 2021 | 829 | 0.130 |
Why?
|
Cost-Benefit Analysis | 3 | 2015 | 983 | 0.130 |
Why?
|
Acute Disease | 3 | 2017 | 2470 | 0.130 |
Why?
|
Aftercare | 1 | 2017 | 256 | 0.130 |
Why?
|
TWEAK Receptor | 1 | 2015 | 4 | 0.130 |
Why?
|
Policy Making | 1 | 2015 | 85 | 0.130 |
Why?
|
Glucosamine | 1 | 2015 | 25 | 0.130 |
Why?
|
Asthma | 1 | 2023 | 904 | 0.130 |
Why?
|
Preoperative Period | 1 | 2016 | 346 | 0.130 |
Why?
|
Genetic Predisposition to Disease | 3 | 2015 | 5712 | 0.130 |
Why?
|
Arkansas | 1 | 2015 | 60 | 0.130 |
Why?
|
International Classification of Diseases | 2 | 2015 | 92 | 0.130 |
Why?
|
Managed Care Programs | 1 | 2015 | 77 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2019 | 412 | 0.120 |
Why?
|
Life Style | 1 | 2018 | 625 | 0.120 |
Why?
|
Skin | 1 | 2020 | 1284 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 2 | 2011 | 1595 | 0.120 |
Why?
|
Writing | 1 | 2015 | 107 | 0.120 |
Why?
|
Hospitals, University | 1 | 2015 | 216 | 0.120 |
Why?
|
Perception | 1 | 2016 | 358 | 0.120 |
Why?
|
Happiness | 1 | 2014 | 14 | 0.120 |
Why?
|
Occupational Diseases | 1 | 2015 | 136 | 0.120 |
Why?
|
Acculturation | 1 | 2015 | 117 | 0.120 |
Why?
|
Ambulatory Care | 1 | 2019 | 579 | 0.120 |
Why?
|
Botrytis | 1 | 2013 | 1 | 0.120 |
Why?
|
Oxylipins | 1 | 2013 | 4 | 0.120 |
Why?
|
Stress, Psychological | 1 | 2021 | 1034 | 0.120 |
Why?
|
Mediterranean Region | 3 | 2018 | 6 | 0.120 |
Why?
|
Mobility Limitation | 1 | 2013 | 30 | 0.120 |
Why?
|
Software | 2 | 2019 | 1355 | 0.120 |
Why?
|
Metabolic Diseases | 1 | 2015 | 137 | 0.120 |
Why?
|
Hand | 1 | 2015 | 175 | 0.110 |
Why?
|
Phytochrome | 1 | 2013 | 1 | 0.110 |
Why?
|
Maternal Mortality | 1 | 2014 | 78 | 0.110 |
Why?
|
Plant Growth Regulators | 1 | 2013 | 13 | 0.110 |
Why?
|
Drug Synergism | 1 | 2017 | 1336 | 0.110 |
Why?
|
Chloroplasts | 1 | 2013 | 12 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2016 | 382 | 0.110 |
Why?
|
Cyclopentanes | 1 | 2013 | 45 | 0.110 |
Why?
|
Hip Prosthesis | 1 | 2013 | 32 | 0.110 |
Why?
|
Drug Costs | 2 | 2011 | 151 | 0.110 |
Why?
|
Diet | 1 | 2021 | 1476 | 0.110 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 1425 | 0.110 |
Why?
|
Referral and Consultation | 1 | 2019 | 935 | 0.110 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 256 | 0.110 |
Why?
|
Absorptiometry, Photon | 2 | 2015 | 242 | 0.110 |
Why?
|
Hyperlipidemias | 1 | 2015 | 247 | 0.110 |
Why?
|
Biomechanical Phenomena | 1 | 2014 | 355 | 0.110 |
Why?
|
Environmental Exposure | 1 | 2015 | 306 | 0.110 |
Why?
|
Illness Behavior | 1 | 2013 | 30 | 0.110 |
Why?
|
Educational Measurement | 1 | 2016 | 410 | 0.110 |
Why?
|
Graft Rejection | 1 | 2017 | 846 | 0.110 |
Why?
|
United States Agency for Healthcare Research and Quality | 1 | 2012 | 13 | 0.110 |
Why?
|
Cementation | 1 | 2012 | 9 | 0.110 |
Why?
|
Motivation | 1 | 2016 | 522 | 0.110 |
Why?
|
Mycobacterium tuberculosis | 1 | 2017 | 464 | 0.110 |
Why?
|
Gene Frequency | 1 | 2015 | 1181 | 0.100 |
Why?
|
Affect | 1 | 2014 | 291 | 0.100 |
Why?
|
Receptors, Interleukin-1 | 1 | 2012 | 96 | 0.100 |
Why?
|
Organizational Objectives | 3 | 2019 | 66 | 0.100 |
Why?
|
Tuberculin Test | 1 | 2013 | 133 | 0.100 |
Why?
|
Secondary Prevention | 2 | 2011 | 341 | 0.100 |
Why?
|
Pyridines | 1 | 2019 | 1291 | 0.100 |
Why?
|
Efficiency, Organizational | 1 | 2012 | 91 | 0.100 |
Why?
|
Bone Morphogenetic Protein 7 | 1 | 2012 | 64 | 0.100 |
Why?
|
Single-Blind Method | 2 | 2011 | 418 | 0.100 |
Why?
|
Alabama | 1 | 2011 | 46 | 0.100 |
Why?
|
Receptors, Interleukin-6 | 1 | 2012 | 66 | 0.100 |
Why?
|
HIV Infections | 2 | 2022 | 2219 | 0.100 |
Why?
|
Quality Improvement | 1 | 2019 | 924 | 0.100 |
Why?
|
Economics, Hospital | 1 | 2011 | 12 | 0.100 |
Why?
|
Hepatitis C | 1 | 2017 | 536 | 0.100 |
Why?
|
Pennsylvania | 1 | 2011 | 71 | 0.100 |
Why?
|
Neglected Diseases | 1 | 2014 | 148 | 0.100 |
Why?
|
Animals | 7 | 2019 | 60947 | 0.100 |
Why?
|
Education, Medical | 1 | 2016 | 362 | 0.100 |
Why?
|
Pharmacogenetics | 1 | 2013 | 263 | 0.100 |
Why?
|
Models, Genetic | 1 | 2015 | 1129 | 0.100 |
Why?
|
Carbon Dioxide | 1 | 2012 | 324 | 0.090 |
Why?
|
B-Lymphocytes | 1 | 2017 | 1353 | 0.090 |
Why?
|
Dietary Sucrose | 1 | 2011 | 42 | 0.090 |
Why?
|
Community Health Services | 1 | 2012 | 131 | 0.090 |
Why?
|
Information Dissemination | 1 | 2013 | 274 | 0.090 |
Why?
|
Biopsy, Needle | 1 | 2015 | 1395 | 0.090 |
Why?
|
Canada | 1 | 2012 | 448 | 0.090 |
Why?
|
Urban Health | 1 | 2010 | 77 | 0.090 |
Why?
|
Patient Dropouts | 1 | 2011 | 91 | 0.090 |
Why?
|
Military Medicine | 1 | 2010 | 55 | 0.090 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 342 | 0.090 |
Why?
|
Metabolic Syndrome | 1 | 2014 | 379 | 0.090 |
Why?
|
Mass Screening | 1 | 2018 | 1568 | 0.090 |
Why?
|
MEDLINE | 1 | 2009 | 38 | 0.090 |
Why?
|
Polyethylene | 1 | 2009 | 22 | 0.090 |
Why?
|
Pyrazoles | 1 | 2018 | 1519 | 0.090 |
Why?
|
Databases, Bibliographic | 1 | 2009 | 28 | 0.090 |
Why?
|
Arthritis, Reactive | 1 | 2009 | 12 | 0.090 |
Why?
|
Caregivers | 3 | 2021 | 729 | 0.080 |
Why?
|
Device Removal | 1 | 2012 | 355 | 0.080 |
Why?
|
Arthritis, Experimental | 1 | 2009 | 43 | 0.080 |
Why?
|
Anti-Inflammatory Agents | 1 | 2012 | 471 | 0.080 |
Why?
|
Sulfonamides | 1 | 2018 | 1896 | 0.080 |
Why?
|
Prosthesis Implantation | 1 | 2011 | 270 | 0.080 |
Why?
|
Polyglycolic Acid | 2 | 2006 | 36 | 0.080 |
Why?
|
Solubility | 1 | 2009 | 248 | 0.080 |
Why?
|
Calcium, Dietary | 1 | 2009 | 55 | 0.080 |
Why?
|
Particle Size | 2 | 2006 | 194 | 0.080 |
Why?
|
Stakeholder Participation | 2 | 2019 | 41 | 0.080 |
Why?
|
Biocompatible Materials | 1 | 2009 | 209 | 0.080 |
Why?
|
Quality Control | 1 | 2009 | 461 | 0.080 |
Why?
|
Muscle Strength | 1 | 2009 | 112 | 0.080 |
Why?
|
Adaptation, Psychological | 1 | 2013 | 790 | 0.080 |
Why?
|
Heart Failure | 2 | 2020 | 2661 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2011 | 691 | 0.080 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2009 | 116 | 0.080 |
Why?
|
Chromatography, Liquid | 1 | 2009 | 359 | 0.080 |
Why?
|
Regulon | 1 | 2007 | 15 | 0.070 |
Why?
|
Hypercholesterolemia | 1 | 2010 | 272 | 0.070 |
Why?
|
N-Glycosyl Hydrolases | 1 | 2007 | 48 | 0.070 |
Why?
|
Clinical Competence | 1 | 2016 | 1366 | 0.070 |
Why?
|
Alcohol Drinking | 1 | 2011 | 599 | 0.070 |
Why?
|
Polymers | 2 | 2006 | 228 | 0.070 |
Why?
|
Internship and Residency | 1 | 2019 | 1475 | 0.070 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2007 | 64 | 0.070 |
Why?
|
Lactic Acid | 2 | 2006 | 310 | 0.070 |
Why?
|
Medication Errors | 1 | 2009 | 175 | 0.070 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2010 | 679 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 496 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 1179 | 0.070 |
Why?
|
Americas | 1 | 2006 | 56 | 0.070 |
Why?
|
Mental Health Services | 1 | 2009 | 257 | 0.070 |
Why?
|
Microscopy, Atomic Force | 1 | 2006 | 30 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 9010 | 0.070 |
Why?
|
Carbon Monoxide | 1 | 2006 | 67 | 0.070 |
Why?
|
Societies, Scientific | 1 | 2006 | 73 | 0.070 |
Why?
|
Erythropoiesis | 1 | 2006 | 74 | 0.070 |
Why?
|
Energy Intake | 1 | 2009 | 525 | 0.070 |
Why?
|
Static Electricity | 1 | 2006 | 62 | 0.070 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2006 | 86 | 0.070 |
Why?
|
Body Composition | 1 | 2009 | 609 | 0.070 |
Why?
|
Caco-2 Cells | 1 | 2006 | 164 | 0.070 |
Why?
|
Surface Properties | 1 | 2006 | 185 | 0.070 |
Why?
|
Nasal Mucosa | 1 | 2006 | 99 | 0.070 |
Why?
|
Administration, Intranasal | 1 | 2006 | 201 | 0.060 |
Why?
|
Immunization, Secondary | 1 | 2006 | 121 | 0.060 |
Why?
|
Injections, Intramuscular | 1 | 2006 | 257 | 0.060 |
Why?
|
Behavior, Animal | 1 | 2009 | 731 | 0.060 |
Why?
|
Poisson Distribution | 1 | 2005 | 93 | 0.060 |
Why?
|
Patient Compliance | 1 | 2009 | 685 | 0.060 |
Why?
|
Endocytosis | 1 | 2006 | 236 | 0.060 |
Why?
|
Child | 4 | 2020 | 30188 | 0.060 |
Why?
|
Phospholipases A | 1 | 2004 | 54 | 0.060 |
Why?
|
Genotype | 1 | 2013 | 4166 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2009 | 523 | 0.060 |
Why?
|
Synovial Membrane | 1 | 2004 | 42 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2017 | 3955 | 0.060 |
Why?
|
Phenotype | 1 | 2015 | 6395 | 0.060 |
Why?
|
Vaccines, DNA | 1 | 2004 | 114 | 0.060 |
Why?
|
Recurrence | 1 | 2012 | 4875 | 0.060 |
Why?
|
Diet, Reducing | 1 | 2024 | 90 | 0.060 |
Why?
|
Gene Expression Regulation | 2 | 2013 | 4065 | 0.060 |
Why?
|
Catastrophization | 1 | 2023 | 12 | 0.060 |
Why?
|
Probability | 1 | 2005 | 889 | 0.050 |
Why?
|
Drug Carriers | 1 | 2004 | 332 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 7962 | 0.050 |
Why?
|
Genes, Recessive | 1 | 2003 | 202 | 0.050 |
Why?
|
DNA Primers | 1 | 2005 | 1421 | 0.050 |
Why?
|
Gene Regulatory Networks | 1 | 2007 | 682 | 0.050 |
Why?
|
Bone Resorption | 1 | 2003 | 137 | 0.050 |
Why?
|
Seroepidemiologic Studies | 1 | 2022 | 128 | 0.050 |
Why?
|
Africa South of the Sahara | 1 | 2022 | 112 | 0.050 |
Why?
|
Immune System | 1 | 2004 | 283 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2007 | 702 | 0.050 |
Why?
|
Patient Selection | 1 | 2010 | 2116 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2378 | 0.050 |
Why?
|
Siblings | 1 | 2003 | 298 | 0.050 |
Why?
|
Infant, Newborn | 4 | 2019 | 8554 | 0.050 |
Why?
|
Nutrition Surveys | 1 | 2023 | 317 | 0.050 |
Why?
|
Interferon-gamma | 1 | 2006 | 1162 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 6269 | 0.050 |
Why?
|
Diphosphates | 1 | 2021 | 13 | 0.050 |
Why?
|
HIV | 1 | 2022 | 232 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2006 | 1057 | 0.050 |
Why?
|
Toxicity Tests | 1 | 2021 | 53 | 0.050 |
Why?
|
Neoplasm Metastasis | 1 | 2011 | 5239 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 2520 | 0.050 |
Why?
|
Translations | 1 | 2020 | 41 | 0.050 |
Why?
|
Muscles | 1 | 2022 | 423 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 3664 | 0.050 |
Why?
|
Germany | 1 | 2020 | 114 | 0.040 |
Why?
|
Anemia | 1 | 2006 | 728 | 0.040 |
Why?
|
Syndrome | 1 | 2003 | 1382 | 0.040 |
Why?
|
DNA, Mitochondrial | 1 | 2022 | 318 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2012 | 10093 | 0.040 |
Why?
|
United Nations | 1 | 2019 | 14 | 0.040 |
Why?
|
Healthy Lifestyle | 1 | 2020 | 45 | 0.040 |
Why?
|
Cause of Death | 2 | 2014 | 796 | 0.040 |
Why?
|
Geography | 1 | 2019 | 142 | 0.040 |
Why?
|
Infant | 4 | 2019 | 13809 | 0.040 |
Why?
|
Lymphocytes | 1 | 2004 | 1237 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2007 | 3146 | 0.040 |
Why?
|
Base Sequence | 1 | 2005 | 4929 | 0.040 |
Why?
|
Death, Sudden, Cardiac | 1 | 2021 | 269 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2011 | 2652 | 0.040 |
Why?
|
Needs Assessment | 1 | 2020 | 247 | 0.040 |
Why?
|
Bone Marrow | 1 | 2006 | 2374 | 0.040 |
Why?
|
Signal Transduction | 2 | 2013 | 12137 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2005 | 6222 | 0.040 |
Why?
|
Fibrosis | 1 | 2022 | 804 | 0.040 |
Why?
|
Organizational Case Studies | 1 | 2017 | 44 | 0.040 |
Why?
|
Colombia | 1 | 2017 | 65 | 0.040 |
Why?
|
Djibouti | 1 | 2017 | 2 | 0.040 |
Why?
|
Somalia | 1 | 2017 | 5 | 0.040 |
Why?
|
Africa, Northern | 1 | 2017 | 13 | 0.040 |
Why?
|
Middle East | 1 | 2017 | 46 | 0.040 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2017 | 43 | 0.040 |
Why?
|
Orthopedics | 1 | 2017 | 76 | 0.030 |
Why?
|
Diuretics | 1 | 2017 | 177 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2022 | 1076 | 0.030 |
Why?
|
Demography | 1 | 2017 | 455 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2018 | 525 | 0.030 |
Why?
|
Pregnancy | 2 | 2022 | 7823 | 0.030 |
Why?
|
Sanitation | 1 | 2015 | 17 | 0.030 |
Why?
|
Mortality, Premature | 1 | 2015 | 12 | 0.030 |
Why?
|
Bariatric Surgery | 1 | 2017 | 125 | 0.030 |
Why?
|
Blood Sedimentation | 1 | 2015 | 39 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2022 | 1328 | 0.030 |
Why?
|
Mitochondria | 1 | 2022 | 1307 | 0.030 |
Why?
|
Ultrasonography, Doppler | 1 | 2015 | 238 | 0.030 |
Why?
|
Occupational Exposure | 1 | 2015 | 251 | 0.030 |
Why?
|
Survival Analysis | 1 | 2005 | 9323 | 0.030 |
Why?
|
Metformin | 1 | 2017 | 390 | 0.030 |
Why?
|
Nutritional Status | 1 | 2015 | 351 | 0.030 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 364 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2005 | 5238 | 0.030 |
Why?
|
Plant Stomata | 1 | 2012 | 7 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2017 | 609 | 0.030 |
Why?
|
Chlorophyll | 1 | 2012 | 16 | 0.030 |
Why?
|
American Recovery and Reinvestment Act | 1 | 2012 | 11 | 0.030 |
Why?
|
Plants, Genetically Modified | 1 | 2012 | 43 | 0.030 |
Why?
|
Electron Transport | 1 | 2012 | 83 | 0.030 |
Why?
|
Economics, Pharmaceutical | 1 | 2012 | 15 | 0.030 |
Why?
|
Child, Preschool | 3 | 2014 | 16787 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 2345 | 0.030 |
Why?
|
Truth Disclosure | 1 | 2014 | 187 | 0.030 |
Why?
|
Drug Administration Routes | 1 | 2011 | 62 | 0.020 |
Why?
|
Joints | 1 | 2011 | 45 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2013 | 729 | 0.020 |
Why?
|
Light | 1 | 2012 | 267 | 0.020 |
Why?
|
Publishing | 1 | 2013 | 224 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2015 | 561 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2015 | 590 | 0.020 |
Why?
|
Genetic Markers | 1 | 2014 | 982 | 0.020 |
Why?
|
Neurodegenerative Diseases | 1 | 2014 | 269 | 0.020 |
Why?
|
Poverty | 1 | 2014 | 498 | 0.020 |
Why?
|
Mice | 3 | 2009 | 35279 | 0.020 |
Why?
|
Multimodal Imaging | 1 | 2015 | 553 | 0.020 |
Why?
|
Health Behavior | 1 | 2015 | 626 | 0.020 |
Why?
|
Drug Interactions | 1 | 2012 | 573 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2014 | 653 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2014 | 444 | 0.020 |
Why?
|
Neuromuscular Agents | 1 | 2009 | 86 | 0.020 |
Why?
|
Focus Groups | 1 | 2008 | 281 | 0.020 |
Why?
|
Kidney | 1 | 2016 | 2198 | 0.020 |
Why?
|
Survivors | 1 | 2013 | 1030 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2012 | 1008 | 0.020 |
Why?
|
Breath Tests | 1 | 2006 | 180 | 0.020 |
Why?
|
Group II Phospholipases A2 | 1 | 2004 | 13 | 0.020 |
Why?
|
Polyethyleneimine | 1 | 2004 | 21 | 0.020 |
Why?
|
Phospholipases A2 | 1 | 2004 | 45 | 0.020 |
Why?
|
CHO Cells | 1 | 2004 | 315 | 0.010 |
Why?
|
Cytosol | 1 | 2004 | 234 | 0.010 |
Why?
|
Hemoglobins | 1 | 2006 | 482 | 0.010 |
Why?
|
Peptides, Cyclic | 1 | 2004 | 138 | 0.010 |
Why?
|
Cricetinae | 1 | 2004 | 712 | 0.010 |
Why?
|
Rats, Wistar | 1 | 2004 | 573 | 0.010 |
Why?
|
Androgens | 1 | 2004 | 519 | 0.010 |
Why?
|
Genetic Variation | 1 | 2009 | 2110 | 0.010 |
Why?
|
Cell Survival | 1 | 2006 | 3061 | 0.010 |
Why?
|
Mice, Nude | 1 | 2004 | 4343 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 1937 | 0.010 |
Why?
|
DNA | 1 | 2004 | 2735 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2009 | 7419 | 0.010 |
Why?
|
Rats | 1 | 2004 | 6204 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 14850 | 0.010 |
Why?
|